Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors

Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors

Introduction Few studies have reported the outcomes of adolescents and young adults (AYAs) with chronic-phase chronic myeloid leukaemia (CML-CP) on tyrosine kinase inhibitors (TKIs).Materials and methods We retrospectively analysed the clinical features, treatment response, and long-term outcomes of...

Full description

Bibliographic Details
Main Authors: Yuriko Nishiyama-Fujita, Tomonori Nakazato, Noriyoshi Iriyama, Michihide Tokuhira, Maho Ishikawa, Eriko Sato, Tomoiku Takaku, Keiji Sugimoto, Hiroyuki Fujita, Isao Fujioka, Shun Tsuchiya, Yuta Kimura, Eisaku Iwanaga, Norio Komatsu, Norio Asou, Masahiro Kizaki, Yoshihiro Hatta, Tatsuya Kawaguchi
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Annals of Medicine
Subjects:
Chronic phase chronic myeloid leukaemia
adolescents and young adults
tyrosine kinase inhibitors
Dasatinib
Nilotinib
Online Access:https://www.tandfonline.com/doi/10.1080/07853890.2022.2069280

Internet

https://www.tandfonline.com/doi/10.1080/07853890.2022.2069280

Similar Items